Sareum Holdings (GB:SAR) has released an update.
Sareum Holdings, a biotech firm focused on developing kinase inhibitors for autoimmune diseases and cancer, has appointed Hybridan LLP as its sole broker. The company is advancing its lead candidate, SDC-1801, targeting TYK2 and JAK1, into Phase 1a/b clinical trials with a focus on psoriasis treatment. Additionally, Sareum is working on SDC-1802 for potential use in cancer immunotherapy.
For further insights into GB:SAR stock, check out TipRanks’ Stock Analysis page.
